Health Policy Insight
Healthcare management online analysis and intelligence
The home of UK health policy

HPI Content

Editorial Thursday 20 February 2014: Will Care.Data Lansleyism prefigure reconfiguration conflagration?

Publish Date/Time: 
02/20/2014 - 15:57

Is it too late to coin the phrase ‘Lansleyism’?

It’s not?

OK, then: the Care.Data fiasco is a near-perfect Lansleyism.

For starters, there’s a pause for six months. That always helps.

More obviously, here comes another technical solution that will revolutionise the NHS, where the communications to the professions and the public was so dramatically poor as to create significant and unanticipated uproar.

I know nostalgia isn’t what it used to be, but this 2010-12 retro is ridiculous.

Editorial Thursday 13 February 2014: Chain reaction and the Comrade-In-Chief on change

Publish Date/Time: 
02/13/2014 - 09:15

Health policy via 18th-century philosopher Jean-Jacques Rousseau? Why not?

Yesterday, Health Service Journal carried a fascinating article flying a kite for the provider landscape to be reshaped into large chains.

Editorial Tuesday 11 February 2014: How is a CSU commercially confidential, Earl Howe?

Publish Date/Time: 
02/11/2014 - 09:46

Now here is An Interesting Things, brought to my attention by Lord Hunt of Kings Heath, Labour's health lead in the House of Lords (Temporal And Spiritual, for ever and ever, Amen).

Lord Hunt's fellow-lord, Lord Rea asked Buttle Of Britain Earl Howe for various details on the costs of commissioning support units (CSUs, of course).

Editorial Tuesday 4 February 2014: Why privatising the NHS would be A Very Bad Idea

Publish Date/Time: 
02/04/2014 - 00:17

The Twittering Classes were fascinated to notice that NHS England's outgoing chief executive, Comrade Sir David Nicholson had joined the micro-blogging service.

The Comrade-In-Chief revealed that he is taking part in a Cambridge University Union debate on the motion that 'This House believes that the NHS should be privatised', which you will be unsurprised to hear he is opposing.

Guest editorial Friday 6 December 2013: Why the NHS definitely needs drones, by CSU Cassander

Publish Date/Time: 
12/06/2013 - 10:47

In this guest editorial, the genius of CSU Cassander is unleashed on solving the woes of the NHS through drone technology - by sheer coincidence, his new commercial sideline

The Maynard Doctrine: It's the clinicians, stupid!

Health economist Professor Alan Maynard reflects on political learning and real reform

Fashions come and fashions go, but clinicians - primarily doctors - still largely determine what healthcare patients receive. They lead the teams that consume £107 billion of taxpayers’ hard-earned money a year. Their vagaries, waste and unwarranted clinical practice variations can determine your survival as much as their energy, humanity and efficiency.

Editorial Tuesday 15 October 2013: Hunt and Burnham dance to The Masochism Tango

Publish Date/Time: 
10/15/2013 - 15:19

‘Beat me!’ begged the masochist.

‘No’, replied the sadist.

Longstanding readers may recall my observation that health policy is BDSM by other means.

Latterly, the relationship between Health Secretary Jeremy ’Bellflinger’ Hunt and his shadow, Mascara Kid Andy Burnham reminds me of Tom Lehrer’s classic ‘The Masochism Tango’:
“I ache for the touch of your lips, dear,

The Maynard Doctrine: A guide to the bollocksfest of NHS management jargon

Health economist Professor Alan Maynard turns his attention to the beautiful world of NHS management jargon

The ways in which NHS staff communicate with each other and the public are a wonder to behold! There is redundant use of adjectives to emphasise perfectly adequate nouns … and then there are phrases which are mis-speaking, misleading or just vacuous.

The latter are charitably collectively known as ‘jargon’. Less charitably, they are known as ‘bollocks’.

The Maynard Doctrine: What to do with “Big Pharma”?

Health economist Professor Alan Maynard examines the ills of Big Pharma, and offers his own prescriptions for improvement.

Big Pharma is struggling, and with a continuing history of naughtiness involving greed and corruption, its critics are out for blood.